Equities

Gubra A/S

Gubra A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)644.00
  • Today's Change38.00 / 6.27%
  • Shares traded53.29k
  • 1 Year change+450.24%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of DKK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments457138116
Total Receivables, Net814490
Total Inventory------
Prepaid expenses3.519.940.71
Other current assets, total------
Total current assets542192207
Property, plant & equipment, net635691
Goodwill, net------
Intangibles, net127.333.71
Long term investments4.414.060.24
Note receivable - long term------
Other long term assets0.00----
Total assets625263302
LIABILITIES
Accounts payable11115.38
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases118.446.54
Other current liabilities, total627592
Total current liabilities8494104
Total long term debt616146
Total debt716952
Deferred income tax--00.55
Minority interest------
Other liabilities, total0.85----
Total liabilities146155151
SHAREHOLDERS EQUITY
Common stock160.130.13
Additional paid-in capital------
Retained earnings (accumulated deficit)463108151
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.00----
Total equity480108151
Total liabilities & shareholders' equity625263302
Total common shares outstanding161616
Treasury shares - common primary issue0.0600
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.